300138.SHE Chenguang Biotech Group
- Market cap
- CNY 6.13B
- P/E
- 18.4x
- P/B
- 1.79x
- ROE
- 10.5%
- Dividend yield
- 2.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300138.SHE undervalued?
Graham number300138.SHE trades 21.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Chenguang Biotech Group fundamental analysis
No fundamental analysis for Chenguang Biotech Group yet.
Chenguang Biotech Group stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Chenguang Biotech Group
ChenGuang Biotech Group Co., Ltd. develops and produces natural colors, spice extracts and essential oils, nutritional and pharmaceutical extracts, and oils and protein. The company offers natural colors, including paprika oleoresin, marigold oleoresin, and turmeric; spice extracts and essential oils, such as capsicum oleoresin, sichuan pepper oil, pepper oleoresin, ginger extract, and cumin oleoresin, fennel oleoresin, celery seed essential oil, litsea cubeba oil, garlic es…
Full company profileChenguang Biotech Group financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Chenguang Biotech Group annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.14B | 2.77B | 3.06B | 3.27B | 3.91B | 4.87B | 6.30B | 6.87B | 6.99B | 6.56B | 6.71B |
| Gross Profit | 293M | 347M | 431M | 573M | 631M | 699M | 844M | 799M | 459M | 439M | 886M |
| Operating Income | 96.5M | 131M | 141M | 203M | 311M | 385M | 487M | 548M | 106M | 439M | 538M |
| EBITDA | 180M | 233M | 276M | 366M | 504M | 583M | 715M | 792M | 392M | 607M | 544M |
| Net Income | 92.5M | 143M | 145M | 194M | 268M | 352M | 434M | 480M | 94.0M | 364M | 360M |
| EPS | 0.18 | 0.28 | 0.28 | 0.38 | 0.53 | 0.67 | 0.81 | 0.90 | 0.18 | 0.76 | 0.75 |
| Balance Sheet | |||||||||||
| Total Assets | 2.49B | 2.87B | 3.36B | 4.51B | 4.65B | 5.96B | 6.92B | 8.54B | 9.02B | 9.50B | 8.89B |
| Total Liabilities | 967M | 1.25B | 1.62B | 2.77B | 2.59B | 3.17B | 3.71B | 5.01B | 5.87B | 6.07B | 5.41B |
| Shareholders' Equity | 1.50B | 1.62B | 1.74B | 1.75B | 2.06B | 2.79B | 3.16B | 3.47B | 3.11B | 3.39B | 3.42B |
| Cash & Short-term Investments | 267M | 127M | 193M | 548M | 310M | 733M | 1.16B | 2.29B | 1.81B | 1.46B | 2.89B |
| Total Debt | 652M | 900M | 1.29B | 2.20B | 2.08B | 2.45B | 2.84B | 3.47B | 3.38B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -322M | -146M | -56.2M | -24.3M | 529M | 63.9M | 735M | -511M | -223M | 213M | - |
| Capital Expenditure | 94.8M | 128M | 140M | 266M | 437M | 281M | 176M | 189M | 150M | 135M | 150M |
| Free Cash Flow | -416M | -274M | -196M | -290M | 92.5M | -217M | 559M | -700M | -372M | 77.7M | 2.99B |
| Ratios | |||||||||||
| ROE | 6.2% | 8.8% | 8.3% | 11.1% | 13.0% | 12.6% | 13.7% | 13.8% | 3.0% | 10.7% | 10.5% |
| ROA | 3.7% | 5.0% | 4.3% | 4.3% | 5.8% | 5.9% | 6.3% | 5.6% | 1.0% | 3.8% | 4.1% |
| Net Profit Margin | 4.3% | 5.2% | 4.7% | 5.9% | 6.8% | 7.2% | 6.9% | 7.0% | 1.3% | 5.5% | 5.4% |
| Debt to Equity | 0.43x | 0.55x | 0.74x | 1.26x | 1.01x | 0.88x | 0.90x | 1.00x | 1.09x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Chenguang Biotech Group dividends
- Dividend yield
- 2.61%
- Forward dividend
- 0.30 CNY
- Payout ratio
- 44.0%
- Ex-dividend date
- May 21, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 160M | 0.34 | 44.0% |
| 2024 | CNY 174M | 0.34 | 185.1% |
| 2023 | CNY 158M | 0.30 | 32.9% |
| 2022 | CNY 69.3M | 0.13 | 16.0% |
| 2021 | CNY 53.3M | 0.10 | 15.2% |
| 2020 | CNY 24.1M | 0.05 | 9.0% |
| 2019 | CNY 40.9M | 0.08 | 21.2% |
| 2018 | CNY 78.0M | 0.15 | 53.7% |
| 2017 | CNY 42.1M | 0.08 | 29.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 27, 2018.
Who owns Chenguang Biotech Group
- Insiders 33.85%
- Institutions 11.10%
- Public & others 55.05%
- Shares outstanding 483M
- Free float 339M
Chenguang Biotech Group company profile
- Company name
- Chenguang Biotech Group
- Ticker
- 300138.SHE
- ISIN
- CNE100000WC5
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Nov 5, 2010
- Sector
- Consumer Defensive
- Industry
- Food Products
- Employees
- 2,079
- Fiscal year end
- December
- Address
- No.1, Chenguang Road, Handan, China, 057250
- Phone
- 86 31 0885 9030
- Website
- cn-cg.com
About Chenguang Biotech Group
ChenGuang Biotech Group Co., Ltd. develops and produces natural colors, spice extracts and essential oils, nutritional and pharmaceutical extracts, and oils and protein. The company offers natural colors, including paprika oleoresin, marigold oleoresin, and turmeric; spice extracts and essential oils, such as capsicum oleoresin, sichuan pepper oil, pepper oleoresin, ginger extract, and cumin oleoresin, fennel oleoresin, celery seed essential oil, litsea cubeba oil, garlic essential oil cinnamon and star anise essential oil; lutein, lycopene, grape seed extract, curcumin, and milk thistle extract; stevia, monk fruit, wheat germ, silybum marianum and grape seed oil, walnut oil, safflower seed oil, flaxseed oil, and animal feed, including Lutein, paprika, crude extract of turmeric, marigold flavonoids. Its products are used in food and beverage, condiment, pharmaceutical, health product, nutritional supplement, cosmetic, and feed additive industries. The company exports its products to Europe, Asia, Southeast Asia, the America, Oceania, Africa and other regions. ChenGuang Biotech Group Co., Ltd. was incorporated in 2000 and is based in Handan, China.
Chenguang Biotech Group management
5- Ms. Ying LuGM & Director · born 1983
- Ms. Jing ZhouCFO, Chief Accountant, Deputy GM, Secretary of the Board & Director · born 1982
- Mr. Wei GaoDeputy General Manager · born 1980
- Mr. Feng Fei LiDeputy General Manager · born 1973
- Mr. Yun He LianDeputy General Manager · born 1972